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Left Atrial Appendectomy and Maze
The feasibility and effectiveness of specific linear left atrial (LA)
lesions to treat atrial fibrillation (AF) were addressed by Kottkamp
et al. (1) in a recent issue of the Journal. Interestingly, linear lesions
confined to the left atrium were able to cure AF in more than 90%
of cases, and the technique was feasible with a minimally invasive
right mini-thoracotomy approach. Although the main objective of
AF cure is the restoration of sinus rhythm, it should be emphasized
that the most dreadful consequence of the disease is embolic
cerebrovascular accidents (CVA). Atrial fibrillation is responsible
for 20% of all strokes, and the risk of stroke is increased fivefold in
nonrheumatic AF and 17-fold in patients with mitral stenosis and
AF (2).
The efficacy of systemic anticoagulation with warfarin to reduce
the incidence of stroke has been demonstrated in randomized
clinical trials, and the left atrial appendage (LAA) has been
recognized as the source of more than 90% of emboli leading to
CVA (3,4). Fifty percent of AF patients are age 75 or older, and
it has been estimated that at least 20% have a contraindication to
warfarin treatment (5). We believe that the importance of the
LAA in the generation of embolic strokes should be addressed
when a surgical approach to AF is contemplated and, therefore, we
are concerned that the procedure proposed by Kottkamp et al. (1)
may result in higher rate of CVA as compared to the classic maze
approach, which includes LA appendectomy (6,7). It has been
demonstrated that the maze procedure is associated with three-
year 100% freedom from thromboembolic complications as com-
pared to 83% in the non-maze group (8). In the study by
Kottkamp et al. (1) surgical ablation was associated with restora-
tion of sinus rhythm and an increase in LAA flow velocity that
could potentially release occult clots into the systemic circulation.
Moreover, oral anticoagulant therapy was prescribed for at least 3
months, the mean follow-up limited to 18 months and the
incidence of CVA not mentioned.
Consequently, we would like the investigators to share their
long-term results on freedom from thromboembolism associated
with the innovative approach proposed. A minimally invasive
method for removing and/or occluding the LAA would provide a
valuable strategy for preventing stroke in patients with AF. Both
percutaneous LAA occlusion and thoracoscopic LAA amputation
have been recently developed, although further studies are needed
to confirm the safety and efficacy of these approaches (7,9).
Additional investigation is needed to determine whether LAA
obliteration, which might have a potential clinical impact similar to
carotid endarterectomy, is effective in preventing thromboembo-
lism and whether it can be advocated as a “must” in the treatment
of a selected population of patients with AF.
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REPLY
We would like to thank Dr. Bonanomi and colleagues for their
interest in our work and for their thorough comments. The
spectrum of patients with atrial fibrillation (AF) is very wide and
varies from the 35-year-old manager with recurrent weekly parox-
ysms of AF resistant to antiarrhythmic drugs and severe symptoms
to the 75-year-old man with hypertension and concomitant
asymptomatic rate-controlled AF. Effective and safe treatment
strategies are available for many patients, and these often consist of
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